Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study
Source: View publication →
The OPTIC trial demonstrated that in patients with a new ICD, the addition of amiodarone to beta-blocker therapy significantly reduced the incidence of ICD shocks compared to sotalol or beta-blocker therapy alone, albeit with an increased frequency of drug-related adverse events.
Key Findings
Study Design
Study Limitations
Clinical Significance
The OPTIC trial provides evidence-based guidance for the pharmacological management of patients with newly implanted ICDs. It highlights that while amiodarone combined with a beta-blocker is superior at reducing painful and anxiety-provoking device shocks, this benefit must be weighed against its well-known side effect profile, making treatment selection a patient-specific decision.
Historical Context
Prior to the OPTIC trial, while ICDs had been established as life-saving therapy for secondary prevention of sudden cardiac death, patients frequently suffered from both appropriate and inappropriate shocks that severely impacted quality of life. Clinicians lacked clear, randomized trial data on the optimal adjunctive antiarrhythmic pharmacotherapy to mitigate these events, often relying on observational data or clinical preference.
Guided Discussion
High-yield insights from every perspective
How do the distinct electrophysiological mechanisms of beta-blockers (Class II) and amiodarone (Class III) synergistically prevent both appropriate and inappropriate ICD shocks?
Key Response
Beta-blockers reduce sympathetic drive and slow the ventricular rate during supraventricular tachycardias (reducing inappropriate shocks), while also increasing the ventricular fibrillation threshold. Amiodarone primarily prolongs the action potential duration and refractory period (Class III effect) but also possesses Class I, II, and IV properties, making it more effective at preventing the onset of ventricular arrhythmias and slowing the rate of fast VT so it falls below the ICD's detection zone or is responsive to anti-tachycardia pacing (ATP).
In a patient who has just received an ICD for secondary prevention, what are the primary clinical trade-offs when choosing amiodarone plus a beta-blocker over sotalol, according to the OPTIC trial findings?
Key Response
The OPTIC trial demonstrated that amiodarone plus a beta-blocker was significantly more effective than sotalol at reducing shocks (hazard ratio 0.43 compared to beta-blocker alone, vs 0.71 for sotalol). However, amiodarone carries a much higher risk of long-term cumulative toxicities (pulmonary, thyroid, hepatic) and had a higher rate of drug discontinuation in the trial (18.2%). Clinical management requires balancing the high efficacy in shock reduction against the burden of monitoring and adverse effects.
The OPTIC trial showed that amiodarone plus beta-blockers was superior for shock prevention, but how does the inclusion of 'inappropriate shocks' in the primary endpoint complicate the clinical application of these results in the era of modern ICD programming?
Key Response
In OPTIC, amiodarone reduced both appropriate and inappropriate shocks. However, modern ICD programming (e.g., MADIT-RIT) uses higher rate cut-offs and longer detection delays to naturally reduce inappropriate shocks without drug toxicity. Therefore, the incremental benefit of amiodarone for 'inappropriate' shock prevention might be less relevant today, shifting the focus of antiarrhythmic drug (AAD) use primarily toward reducing the burden of appropriate shocks and treated VT episodes.
Considering the high discontinuation rate of amiodarone due to side effects in the OPTIC trial, how should the trial's findings influence the decision to initiate 'upstream' antiarrhythmic therapy at the time of ICD implantation versus a 'wait-and-see' approach?
Key Response
While OPTIC shows combination therapy is most effective at preventing the first shock, the toxicity profile suggests that 'proactive' amiodarone for all ICD recipients is likely inappropriate. Instead, therapy should be individualized. In patients where a single shock could be catastrophic (e.g., severe heart failure, high anxiety, or hazardous occupations), the OPTIC data supports early amiodarone. For others, starting with beta-blockers alone and escalating to AADs only after a shock occurs remains a more balanced strategy to avoid unnecessary drug-related morbidity.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the use of a composite primary endpoint of 'any ICD shock' (both appropriate and inappropriate) in the OPTIC study from a statistical power and mechanistic specificity perspective.
Key Response
Using a composite endpoint increases the event rate, thereby increasing the statistical power of the study to find a difference between groups. However, it lacks mechanistic specificity because amiodarone affects ventricular substrate (appropriate shocks) and atrial/AV nodal conduction (inappropriate shocks) through different pathways. If the effect size is driven primarily by one component (e.g., reduction in AF-related shocks), the study might overstate the drug's efficacy in preventing life-threatening ventricular arrhythmias, which is the primary reason for the ICD.
The OPTIC trial was an open-label study; how might the lack of blinding have introduced bias in the reporting of adverse events and the decision-making process for drug discontinuation or crossover?
Key Response
In an open-label trial, both patients and investigators are aware of the treatment assignment. This can lead to 'expectation bias,' where patients on amiodarone are more likely to attribute non-specific symptoms to the drug because of its well-known side-effect profile, potentially inflating the reported adverse event rates. Conversely, investigators might be more likely to switch patients to the 'superior' arm (amiodarone) after a shock, which can complicate the intention-to-treat analysis and the assessment of drug durability.
How do the findings of the OPTIC trial align with current AHA/ACC/HRS guidelines regarding the use of antiarrhythmic drugs for ICD shock prevention, and is there sufficient evidence to elevate combination therapy to a Class I recommendation?
Key Response
Current guidelines (e.g., 2017 AHA/ACC/HRS) typically give amiodarone a Class IIa recommendation for reducing shocks in ICD patients who experience recurrent symptomatic arrhythmias. Despite OPTIC's clear evidence of efficacy, it is unlikely to be elevated to Class I for all patients because the absolute reduction in shocks must be weighed against the lack of mortality benefit and the significant side-effect profile. Guidelines emphasize using the lowest effective dose and often reserve amiodarone for patients who fail beta-blocker therapy alone.
Clinical Landscape
Noteworthy Related Trials
AVID Trial
Tested
Implantable cardioverter defibrillator (ICD)
Population
Patients with a history of ventricular fibrillation or hemodynamically unstable ventricular tachycardia
Comparator
Antiarrhythmic drugs (primarily amiodarone)
Endpoint
All-cause mortality
CASH Trial
Tested
Implantable cardioverter defibrillator (ICD)
Population
Patients who survived cardiac arrest
Comparator
Antiarrhythmic drugs (metoprolol, propafenone, or amiodarone)
Endpoint
Total mortality
CIDS Trial
Tested
Implantable cardioverter defibrillator (ICD)
Population
Patients with a life-threatening ventricular arrhythmia
Comparator
Amiodarone
Endpoint
All-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis